Sclerosis News and Research RSS Feed - Sclerosis News and Research

Wayne State University awarded grant to explore new MS pathology model

Wayne State University awarded grant to explore new MS pathology model

The National Multiple Sclerosis Society has provided a grant to a Wayne State University School of Medicine professor to explore a new model of MS pathology. [More]
Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the development of groundbreaking drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), announced today that Robert G. Miller, M.D., Director of the Forbes Norris MDA/ALS Research Center at Sutter Health's California Pacific Medical Center in San Francisco, has been awarded a grant from The ALS Association for $1.5 million to help fund a Phase 2 clinical study of the company's investigational therapy for ALS, NP001. [More]

ALS ACT initiative to speed discovery of new ALS treatments

The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) initiative. [More]
University of Oslo researchers find the cause of coeliac disease

University of Oslo researchers find the cause of coeliac disease

Professor Ludvig M. Sollid and his colleagues at the University of Oslo have found the cause of coeliac disease. To do so required really going into depth, right down to molecular level. [More]
UNSW Australia to co-host sixth International Nanomedicine Conference in Sydney

UNSW Australia to co-host sixth International Nanomedicine Conference in Sydney

Advances in nanotechnology and nano-fabrication are fundamentally changing the future of medicine, enabling more effective diagnostics and targeted drugs, and new bioactive materials that can help repair our bodies. [More]
Kay E. Davies named recipient of ASHG's 2015 William Allan Award

Kay E. Davies named recipient of ASHG's 2015 William Allan Award

The American Society of Human Genetics has named Kay E. Davies, DPhil, Dr. Lee's professor of anatomy, associate head of the medical sciences division; and director of the Medical Research Council Functional Genomics Unit in the department of physiology, anatomy and genetics at the University of Oxford, the 2015 recipient of the annual William Allan Award. [More]
Synthetic Biologics announces initiation of SYN-010 Phase 2 clinical trial for treatment of IBS-C

Synthetic Biologics announces initiation of SYN-010 Phase 2 clinical trial for treatment of IBS-C

Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, reported the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C). [More]
Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

Neuralstem, Inc., a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden. [More]

Amy Schumer promises 'disappointing lap dance' for winner of TrainWreck Premiere contest to support MS research

Amy Schumer, writer and star of the upcoming comedy, TrainWreck, has promised a 'disappointing lap dance' for the winner of Universal's TrainWreck Premiere Experience hosted on CrowdRise to benefit the National Multiple Sclerosis (MS) Society, an organization that is very dear to her heart. [More]
Cannabis and Cannabinoid Research journal supports President Obama's statement on medical use of marijuana

Cannabis and Cannabinoid Research journal supports President Obama's statement on medical use of marijuana

Mary Ann Liebert, publisher of the newly launched peer-reviewed open access journal Cannabis and Cannabinoid Research, strongly supports President Obama's statement that "...carefully prescribed medical use of marijuana may in fact be appropriate and we should follow the science as opposed to ideology on this issue," when asked about a pending Senate bill seeking to change federal law regarding state-legalized medical marijuana programs. [More]
Errors on memory and thinking tests may signal Alzheimer's 18 years before diagnosis

Errors on memory and thinking tests may signal Alzheimer's 18 years before diagnosis

A new study suggests that errors on memory and thinking tests may signal Alzheimer's up to 18 years before the disease can be diagnosed. The research is published in the June 24, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA). [More]
OhioHealth Neuroscience Center launched at Riverside Methodist Hospital

OhioHealth Neuroscience Center launched at Riverside Methodist Hospital

On July 6, 2015, OhioHealth will open its doors to the new OhioHealth Neuroscience Center on Riverside Methodist Hospital's campus. [More]
Stanford researchers find how neurons work together to control movement in people with paralysis

Stanford researchers find how neurons work together to control movement in people with paralysis

Stanford University researchers studying how the brain controls movement in people with paralysis, related to their diagnosis of Lou Gehrig's disease, have found that groups of neurons work together, firing in complex rhythms to signal muscles about when and where to move. [More]
Ontario announces $25 million investment to support new treatments for people with chronic diseases

Ontario announces $25 million investment to support new treatments for people with chronic diseases

Ontario is investing $25 million over five years to support new treatments and therapies for people living with chronic diseases, such as cancer, multiple sclerosis and diabetes. [More]
Biotin benefits ‘clinically relevant’ in progressive multiple sclerosis

Biotin benefits ‘clinically relevant’ in progressive multiple sclerosis

Patients with progressive multiple sclerosis and their clinicians see clear improvements during treatment with a high dose of biotin, show further results from the phase III trial of the therapy. [More]
New research sheds light on molecular architecture of receptors linked to many brain diseases

New research sheds light on molecular architecture of receptors linked to many brain diseases

Scientists at The Scripps Research Institute have teamed up with several other institutions and pharmaceutical companies, including the University of Southern California (USC), San Diego's Receptos Inc. and Japanese company Ono Pharmaceutical Co., Ltd., to publish the first 3D structures of a receptor implicated in many diseases of the brain and in normal physiology throughout the body. [More]
MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

MedDay, a biotechnology company focused on the treatment of nervous system disorders, reports additional positive data from its pivotal Phase III clinical trial, MS-SPI, with MD1003, a highly-concentrated pharmaceutical grade biotin, in patients with Progressive Multiple Sclerosis. [More]
LMU clinicians reveal mechanism involved in determining lifetime of antibody-producing cells

LMU clinicians reveal mechanism involved in determining lifetime of antibody-producing cells

Clinicians at Ludwig-Maximilians-Universitaet in Munich have elucidated a mechanism involved in determining the lifespan of antibody-producing cells, and identified a promising new biomarker for monitoring autoimmune diseases like multiple sclerosis and lupus erythematosus. [More]
Study identifies unique bacterial signature in people with systemic sclerosis

Study identifies unique bacterial signature in people with systemic sclerosis

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) Press Conference showed that people with systemic sclerosis (SSc) have a unique bacterial signature in their colon, when compared with healthy people. [More]
Advertisement
Advertisement